Monkey CD47 Stable Cell Line - CHO-K1

Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients using rituximab and the CHOP regimen commonly encounters challenges due to both inherent and acquired resistance mechanisms. The researchers investigated the novel bispecific fusion protein DSP107 for treating DLBCL. DSP107 targets the CD47:SIRPα signaling axis to enhance phagocytosis by macrophages and trogocytosis by PMNs against DLBCL cells. It also activates 4-1BB-mediated costimulatory signaling in T cells, boosting their anticancer activity. In vitro and in vivo studies demonstrated DSP107's ability to significantly reduce cancer cell numbers and tumor size, particularly when combined with rituximab. Safety evaluations in cynomolgus monkeys showed a favorable profile. These findings suggest that DSP107 is a promising therapeutic strategy for enhancing innate and adaptive immune responses in DLBCL treatment.

Figure 1. The researchers demonstrated that DSP107-mediated activation of T cell costimulatory signaling through 4-1BB requires specific binding to CD47, evidenced by increased IL-8 secretion upon cross-linking. (Cendrowicz E, et al., 2022)

Creative Biogene offers the Monkey CD47 Stable Cell Line—CHO-K1, designed for applications in cancer research and immunotherapy. This cell line can effectively explore CD47 interactions in immune response studies.